{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-024663","form_type":"8-K","ticker":"NRC","cik":"0000070487","company_name":"NRC HEALTH","filed_at":"2026-07-28T20:03:12+00:00","discovered_at":"2026-07-28T20:04:00.601658+00:00","generated_at":"2026-07-28T20:04:10.573557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NRC Health Q2 TRCV up 11% to $151.9M; adj. EPS $0.31 vs. GAAP loss ($0.15)","bullets":["Total revenue $35.4M, up 4% YoY; GAAP net loss ($3.3M) vs. adjusted net income $6.9M.","Adjusted EBITDA $9.4M (27% of revenue); free cash flow $0.1M after $2.9M cash payment for accelerated vesting.","TRCV $151.9M, up 11% YoY; strongest bookings for The Governance Institute in seven years.","GAAP diluted EPS ($0.15); adjusted diluted EPS $0.31 on 22.0M shares.","CEO cites double-digit TRCV growth, strong go-to-market execution, and product innovation commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-024663","json":"https://secwatch.observer/filing/0001437749-26-024663.json","markdown":"https://secwatch.observer/filing/0001437749-26-024663.md","text":"https://secwatch.observer/filing/0001437749-26-024663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/70487/000143774926024663/0001437749-26-024663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/70487/000143774926024663/nrc20260724_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T20:04:10.573557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}